Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2008

View Archived Issues

IGF-I elevations last over one week after single injection of NNC-126-0083

Recent AstraZeneca patents describe new imaging agents

CNTO-328 demonstrates activity in ovarian cancer trial

New p38alpha MAPK inhibitors disclosed in recent Almirall patent

Recent Takeda patent reports new 5-HT2C receptor agonists for urinary incontinence

Diabetes candidate ARRY-403 to advance to clinical investigation

Ranbaxy submits IND in India to initiate phase I trials of respiratory inflammation candidate

Vernalis receives milestone payment from Servier under oncology drug program

Acusphere's Imagify to be reviewed at FDA Advisory Committee Meeting in December 2008

New agents for treating endocrine disorders divulged in recent patent literature

King Pharmaceuticals extends tender offer until November 2008 to acquire Alpharma

PharmAthene raises USD 13.1 million in strategic equity financing with Panacea Biotec

NVA-237 provides bronchodilation to COPD patients in phase II studies

Differin gel to be launched in Japan for topical treatment of acne vulgaris

Dr. Reddy's subsidiary launches EpiCeram skin barrier emulsion

Lisofylline to be studied in phase II trial to improve islet cell transplant outcomes

Omrix receives EMEA approval for Evicel liquid fibrin sealant

Pfizer launches Macugen for age-related macular degeneration in Japan

Acura and King present top-line results for Acurox in abuse liability

Neurogen reports results from phase II trials of aplindore in RLS and PD

Nile reports interim data from phase IIa CD-NP study in heart failure

TB Alliance and sanofi aventis enter collaboration for new TB drugs

MMRC initiates phase Ib study of elotuzumab in combination with Revlimid and dexamethasone

R&D highlights from the UBS Global Life Sciences Conference in New York: Orexigen Therapeutics

Overall survival and safety data on elesclomol reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...